| 000 | 01845 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250511181528.0 | ||
| 264 | 0 | _c19930302 | |
| 008 | 199303s 0 0 eng d | ||
| 022 | _a0014-2999 | ||
| 024 | 7 |
_a10.1016/0014-2999(92)90556-j _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKebabian, J W | |
| 245 | 0 | 0 |
_aA-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. _h[electronic resource] |
| 260 |
_bEuropean journal of pharmacology _cDec 1992 |
||
| 300 |
_a203-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_a1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine _xpharmacology |
| 650 | 0 | 4 |
_a2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine _xpharmacology |
| 650 | 0 | 4 |
_aAdamantane _xadministration & dosage |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBenzazepines _xpharmacology |
| 650 | 0 | 4 |
_aBenzopyrans _xadministration & dosage |
| 650 | 0 | 4 | _aBinding Sites |
| 650 | 0 | 4 | _aCallithrix |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 |
_aDopamine Agents _xadministration & dosage |
| 650 | 0 | 4 | _aFishes |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 |
_aOxidopamine _xpharmacology |
| 650 | 0 | 4 |
_aParkinson Disease, Secondary _xchemically induced |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_aReceptors, Dopamine D1 _xdrug effects |
| 700 | 1 | _aBritton, D R | |
| 700 | 1 | _aDeNinno, M P | |
| 700 | 1 | _aPerner, R | |
| 700 | 1 | _aSmith, L | |
| 700 | 1 | _aJenner, P | |
| 700 | 1 | _aSchoenleber, R | |
| 700 | 1 | _aWilliams, M | |
| 773 | 0 |
_tEuropean journal of pharmacology _gvol. 229 _gno. 2-3 _gp. 203-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0014-2999(92)90556-j _zAvailable from publisher's website |
| 999 |
_c1369200 _d1369200 |
||